3 Things About Moderna That Smart Investors Know

3 Things About Moderna That Smart Investors Know
·4 min read

Moderna debuted in 2018 with the most lucrative initial public offering in biotech history. To that point, the company had existed for eight years and burned through $1.4 billion with no products to show for it. Unlike other biotech companies, Moderna was touting a drug development platform -- using messenger RNA (mRNA) to deliver protein-making instructions to cells -- rather than any individual therapy.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting